Top Markets
Coin of the day
Poolbeg Pharma PLC Poolbeg Pharma PLC

Poolbeg Pharma PLC

POLB
Rangering i aksjer #38628
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the... Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Aksjekurs
$0.11565963
Markedsverdi
$882.99K
Endring (1 dag)
-2.30%
Endring (1 år)
189.81%
Land
GB
Handel Poolbeg Pharma PLC (POLB)

Kategori

P/S-forhold for Poolbeg Pharma PLC (POLB)
P/S-forhold per 2026 TTM: 0
Ifølge Poolbeg Pharma PLC sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Poolbeg Pharma PLC fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE